CARsgen Presents Research Results on Satri-cel in The Lancet and at the 2025 ASCO Annual Meeting
The article in The Lancet was titled "Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial". Full article available at: https://doi.org/10.1016/S0140-6736(25)00860-8.
The oral presentation at the 2025 ASCO Annual Meeting (Abstract 4003) was titled "Claudin18.2-specific CAR T cells (Satri-cel) versus treatment of physician's choice (TPC) for previously treated advanced gastric or gastroesophageal junction cancer (G/GEJC): Primary results from a randomized, open-label, phase II trial (CT041-ST-01)".
Professor Lin Shen from Beijing Cancer Hospital, the principal investigator of this study, said, "The CT041-ST-01 trial represents the world's first randomized controlled clinical study of CAR-T cell therapy for solid tumors. In patients with heavily pretreated, advanced gastric/gastroesophageal junction cancer who have extremely limited treatment options and poor prognosis, satri-cel has demonstrated breakthrough efficacy with significant clinical benefits, including much improved progression-free survival (PFS), overall survival (OS), and tumor response rates. This brings new hope to patients with otherwise medically untreatable conditions. We are further exploring satri-cel's potential in adjuvant settings and as first-line sequential therapies, aiming to intervene earlier in the disease course, extend patients' survival, and ultimately pursue potential cures."
Dr. Zonghai Li, Founder, Chairman of the Board, Chief Executive Officer, and Chief Scientific Officer of CARsgen Therapeutics, said, "We are honored that the CT041-ST-01 study results were published in The Lancet—a premier, global medical journal—and presented at the 2025 ASCO Annual Meeting. The positive result of this randomized controlled trial marks a major milestone in solid tumor CAR-T therapy. These achievements are a testament to the whole research team's years of dedication, and we extend our deepest gratitude to patients and their families for their trust and participation. This year, satri-cel has been granted Breakthrough Therapy Designation and Priority Review by the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) for the treatment of Claudin18.2-positive advanced gastric/gastroesophageal junction adenocarcinoma (G/GEJA) in patients who have failed at least two prior lines of therapy. We plan to submit a New Drug Application (NDA) for satri-cel to the NMPA this month and anticipate its approval as the world's first commercially available CAR-T product for solid tumors, bringing benefits to patients."
About Satri-cel
Satri-cel is an autologous CAR T-cell product candidate against the protein Claudin18.2 that has the potential to be the first-in-class globally. Satri-cel targets the treatment of Claudin18.2-positive solid tumors with a primary focus on G/GEJA and pancreatic cancer (PC). Initiated trials include investigator-initiated trials (CT041-CG4006, NCT03874897), a confirmatory Phase II clinical trial for advanced G/GEJA in China (CT041-ST-01, NCT04581473), a Phase Ib clinical trial for PC adjuvant therapy in China (CT041-ST-05, NCT05911217), an investigator-initiated trial for satri-cel be used as consolidation treatment following adjuvant therapy in patients with resected G/GEJA (CT041-CG4010, NCT06857786), and a Phase 1b/2 clinical trial for advanced gastric or pancreatic adenocarcinoma in North America (CT041-ST-02, NCT04404595).
Satri-cel has been granted Priority Review by the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) for the treatment of Claudin18.2-positive advanced G/GEJA in patients who have failed at least two prior lines of therapy in May 2025. Satri-cel has been granted Breakthrough Therapy Designation by the CDE of China's NMPA for the treatment of Claudin18.2-positive advanced G/GEJA in patients who have failed at least two prior lines of therapy in March 2025. Satri-cel was granted Regenerative Medicine Advanced Therapy designation by U.S. FDA for the treatment of advanced G/GEJA with Claudin18.2-positive tumors in January 2022. Satri-cel received Orphan Drug designation from the U.S. FDA in September 2020 for the treatment of G/GEJA.
About CARsgen Therapeutics Holdings Limited
CARsgen is a biopharmaceutical company focusing on developing innovative CAR T-cell therapies to address the unmet clinical needs including but not limited to hematologic malignancies, solid tumors and autoimmune diseases. CARsgen has established end-to-end capabilities for CAR T-cell research and development covering target discovery, preclinical research, product clinical development, and commercial-scale production. CARsgen has developed novel in-house technologies and a product pipeline with global rights to address challenges faced by existing CAR T-cell therapies. Efforts include improving safety profile, enhancing the efficacy in treating solid tumors, and reducing treatment costs, etc. CARsgen's mission is to be a global biopharmaceutical leader that provides innovative and differentiated cell therapies for patients worldwide and makes cancer and other diseases curable.
Forward-looking Statements
All statements in this press release that are not historical fact or that do not relate to present facts or current conditions are forward-looking statements. Such forward-looking statements express the Group's current views, projections, beliefs and expectations with respect to future events as of the date of this press release. Such forward-looking statements are based on a number of assumptions and factors beyond the Group's control. As a result, they are subject to significant risks and uncertainties, and actual events or results may differ materially from these forward-looking statements and the forward-looking events discussed in this press release might not occur. Such risks and uncertainties include, but are not limited to, those detailed under the heading "Principal Risks and Uncertainties" in our most recent annual report and interim report and other announcements and reports made available on our corporate website, https://www.carsgen.com. No representation or warranty is given as to the achievement or reasonableness of, and no reliance should be placed on, any projections, targets, estimates or forecasts contained in this press release.
Contact CARsgen
For more information, please visit https://www.carsgen.com/
View original content to download multimedia:https://www.prnewswire.com/news-releases/carsgen-presents-research-results-on-satri-cel-in-the-lancet-and-at-the-2025-asco-annual-meeting-302470028.html
SOURCE CARsgen Therapeutics
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
5 hours ago
- Associated Press
DermRays Celebrates 13 Years of Skincare Innovation with Exclusive Anniversary Sale and Groundbreaking 1450nm Laser Device for 2026
PLEASANTON, Calif., Aug. 15, 2025 /PRNewswire/ -- DermRays, a pioneer in at-home skincare technology, marks its 13th anniversary with a celebration of its best-selling devices and a sneak peek at its upcoming 1450nm laser skincare tool, slated for launch in early 2026. This milestone underscores the brands commitment to merging cutting-edge science with accessible beauty solutions. Anniversary Spotlight: Award-Winning Skincare Heroes To thank customers for their trust, DermRays is offering limited-time discounts on three transformative devices designed to rejuvenate skin at home: 1. DermRays Revive The first and only at-home laser with ultra-high energy for collagen regeneration. Ideal for reducing fine lines and boosting collagen, its a clinic-grade tool for a fraction of the cost. Revive uses cutting-edge 1064nm laser technology, the same as that employed by leading salon brands. 2. FusionGlow Multi-Functional Microcurrent Toning Device Beyond Microcurrent: 5 Skincare Technologies You Need. Comprehensive Skin Revitalization: Brighten, Hydrate, Rejuvenate. Achieve radiant, firm skin in 14 days with clinically visible results backed by SGS. 3. LED Light Therapy Silicone Mask Your daily skincare companion: blue, red, infrared, and mixed light for every need. Only 15 minutes a day for youthful and radiant skin. 'For 13 years, we've empowered users to take control of their skincare routines with safe, effective technology,' says Dr. Yang Lin, Brand Director at DermRays. 'Our anniversary sale is a tribute to our community-and just the beginning of whats next.' 4. The Future: 1450nm Laser Skincare Device DermRays is set to revolutionize at-home treatments again with its 1450nm laser device (expected Q1 2026). It stimulates natural collagen production to smooth fine lines, restore firmness, and reverse signs of aging. This tool will expand the brands professional-grade offerings, bridging the gap between spa treatments and home care. Join the Celebration From August 1-31, 2025, enjoy exclusive anniversary bundles and discounts on DermRays bestselling devices. Follow @DermRays on social media for giveaways and live demos. About DermRays Since 2011, DermRays has combined dermatological research with accessible technology, offering FDA/CE/UKCA-cleared, non-invasive devices for radiant, youthful skin at home. View original content to download multimedia: SOURCE DermRays
Yahoo
14 hours ago
- Yahoo
Meyers Manx and Tuthill Debut the LFG at The Quail, A Motorsports Gathering
A new era in luxury off-road adventure, launching with six years of curated global driving experiences MONTEREY, Calif., Aug. 15, 2025 /PRNewswire/ -- At the prestigious The Quail, A Motorsports Gathering during Monterey Car Week, Meyers Manx, the legendary creator of the original fiberglass dune buggy, and world-renowned rally specialists Tuthill unveiled the LFG, a limited-production off-road performance machine set to redefine the spirit of recreational driving. Only 100 examples of the LFG will be built, each offering owners exclusive access to six years of meticulously planned driving adventures across the globe. The journey begins in 2027 with the inaugural LFG Baja Tour, marking the 50th anniversary of Meyers Manx's historic victory in the first Mexican 1000 (now the Baja 1000). Designed for those who crave both comfort and capability, the LFG merges cutting-edge engineering with a playful, adventurous spirit. Underneath its carbon fiber body and ROPS (Roll Over Protection Structure) lies a choice of high-performance engines — including a 4-valve variant derived from Tuthill's celebrated "K" — paired with a six-speed sequential gearbox and 4WD featuring front, center, and rear limited-slip differentials. Twin five-way adjustable dampers with hydraulic bump stops, and BF Goodrich All-Terrain tyres ensure the LFG is equally at home crossing desert dunes or carving through rugged mountain trails. Inside, a bespoke, climate-controlled cabin offers comfort on long hauls, while an Inconel exhaust, integrated GPS, and long-range fuel tank prepare the vehicle for journeys well beyond the beaten path. In moments, the enclosed cockpit can transform into an open-air buggy, letting drivers and passengers fully embrace the elements. "This project started as a dream between my long-time pal Richard and me, both in constant pursuit of the ultimate expression of freedom and performance," said Phillip Sarofim, Founder and CEO of Trousdale Ventures and Chairman of the Board at Meyers Manx. "We imagined the perfect Meyers Manx, brought Freeman Thomas on board to infuse his design brilliance, and merged it with Tuthill's engineering mastery. The result is raw, visceral, novel, and totally uncompromising. We call it LFG for a reason." "It's fairly well known that I love experiences, I love the effect it has on those that join us wherever we go," said Richard Tuthill, Director at Tuthill. "This, however, is slightly different. We are not necessarily bringing the stopwatch with us on these trips. I want to take people to see the most amazing parts of the world. I have been super lucky to see some life-changing scenery whilst Rallying, the memories I have as a result are immeasurable. These things change you. I think for the better. We crave experiences that we can look back on for the rest of our lives. We now have an amazing car to help us to create these in a unique way. The car looks fun, mischievous, it has a character that I have genuinely never seen or felt. BUT underneath it's PROPER – could we go to the moon and back in it? Probably yes, it has the capability to go wherever we point it, and we can do it safely and comfortably. In 2 minutes, it transforms from a fully air-conditioned enclosed cabin to a doorless buggy where the wind provides the air that helps us smile. It's very special. I can't wait to get started, please join in – LFG." More details, images, and specifications are available online. About Meyers ManxFounded in 1964 by Bruce Meyers, Meyers Manx is the creator of the original fiberglass dune buggy — an enduring symbol of freedom, adventure, and off-road performance. The brand blends innovation with heritage, inspiring generations of adventurers worldwide. Today, Meyers Manx continues to pioneer the future of recreational and off-road vehicles through a fusion of timeless design and modern engineering. Press Contactinfo@ About TuthillTuthill is a family-owned business based in Oxfordshire, UK, with over 50 years of success in rallying and racing. Known for building high-performance vehicles for both tarmac and off-road terrain, the company's legacy began with Francis Tuthill's participation in the 1977 London to Sydney Marathon. Now under second-generation leadership, Tuthill continues to deliver reliability, competitiveness, and desirability through motorsport and road car programs, including the acclaimed Tuthill K and GT ONE. Press ContactSales Inquiries: David Cox & Richard Tuthill — lfg@ | +44 (0) 1295 750 514Brand & Partnerships: Pia Jarak — pia@ Media Inquiries: Laura Harris — media@ View original content to download multimedia: SOURCE Meyers Manx Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Forbes
15 hours ago
- Forbes
The Prototype: AI Tools May Degrade Doctors' Skills
In this week's edition of The Prototype, we look at the risk of depending on AI to 'think' for you, mass-producing satellites, a startup helping NASA avoid space junk, and more. To get The Prototype in your inbox, sign up here . A study published this week in The Lancet examined the impact of an AI tool for colonoscopies on the skills of doctors. The researchers tested doctors' abilities to find certain abnormalities in patients for three months before using AI, then tested them again after they'd used the tool for three months. They found that doctors' ability to spot those abnormalities on their own degraded after using AI. And while that might not be a big deal a few decades down the road when AI-assisted detections are the norm, it does pose a problem right now, because these tools aren't universal. A doctor accustomed to using AI at one hospital might find their performance declines working at a hospital that hasn't adopted it yet. It also raises larger questions about letting AI do your 'thinking' for you, because what's lost might be more than one particular skill. Studies have shown, for example, that overreliance on GPS for driving could degrade your spatial memory. As we enter a brave new world of AI, it will be increasingly important to not only know how to use it, but also when not to use it. Stay tuned. Apex Wants To Bring Henry Ford-Style Mass Production To Satellites S atellite manufacturing has long been a bespoke business with spacecraft customized for the missions they are sent on. Elevated costs and delays come with the territory. With more and more small satellites being launched into low-Earth orbit, Lost Angeles-based Apex has developed standardized spacecraft it says are a faster and more affordable option. The company is marketing three standardized satellite bodies with power and control systems that can be quickly customized by clients with sensors and payloads. Like, say, weapons to shoot down intercontinental ballistic missiles, as envisioned for President Trump's Golden Dome. Similar to automakers, Apex offers different versions of its satellites, with options like more power, a fancier communications system and a choice between electrical or chemical propulsion. 'You either take it or you leave it,' CEO Ian Cinnamon said. Read the whole story at Forbes . DISCOVERY OF THE WEEK: DEVICE LETS USERS COMMUNICATE WITH THOUGHTS Neurological disorders like ALS can make it difficult for people to communicate. And while there are devices that can help them speak, they're often much slower than the speech that people take for granted. A team of researchers have invented a new device that may change this: a computer device implanted in the brain that can pick up the neural activity associated with speech-based thinking and translate it into words. The technology is still in its infancy, but opens the door to brain-computer interfaces that may one day give patients the ability to communicate as quickly as they think. FINAL FRONTIER: LEOLABS WANTS TO HELP NASA AVOID SPACE JUNK Menlo Park, Calif.-based space startup LeoLabs has entered into an agreement for NASA to evaluate its data for use in evaluating the risk of satellite and spacecraft collisions. The goal would be to integrate LeoLabs' data, which is collected by multiple radar systems around the world, with the Air Force radar systems that NASA currently uses to track objects in space. (To learn more about LeoLabs, check out a story I wrote about the company a few years back.) FORBES CALLED IT: HELPING DOGS LIVE LONGER Every year, Forbes selects 25 VC-backed companies for our Next Billion-Dollar Startups List, highlighting those whose growth puts them on track to become worth $1 billion or more. Making the list this year is biotech startup Loyal, which is developing pills that could extend dogs' lifespans. The company is currently testing its medication on several hundred canines in a clinical trial, with hopes of bringing it to market soon. We've had our eye on Loyal for a few years now: its founder, Celine Halioua, is an alumna of our 30 Under 30 list, and I wrote about her company's progress a couple of years ago. If Loyal is successful in extending the life of dogs, its next goal will be even more ambitious: extending ours. 'I think the general public will be blown away when they realize they can go to the vet and get a drug to extend their dogs' lifespan,' Halioua told my colleague Amy Feldman. 'Then they'll ask, 'Why can't I do this for my grandma?'' WHAT ELSE I WROTE THIS WEEK Earlier this week, I wrote about biotech startup Tahoe Therapeutics, which just raised $30 million in investment to support scaling up its dataset of how different molecules interact with living cells. Their goal? To train AI models to simulate cells as a way to accelerate the discovery of new medicines. Right now, data is the limiting factor in training AI, but recently the company released a dataset with 100 million cellular datapoints to improve those models. In my other newsletter, InnovationRx, Amy Feldman and I looked at how misinformation about vaccines led to the recent shooting at the CDC, a company building programmable mRNA to fight cancer, Robert F. Kennedy Jr.'s fight with a medical journal, and more. SCIENCE AND TECH TIDBITS The federal government has pulled funds for California's high-speed rail, but the project may have an unlikely savior: AI data centers. Google is teaming up with pollster Scott Rasmussen for a project that would use AI to produce better political polling outcomes. Researchers at Texas A&M have developed a new carbon-fiber material that can heal itself when broken and is harder than steel. Scientists have developed a 'skin in a syringe'—a gel that contains living skin cells–that can be 3D printed into a skin graft and applied to a wound, enabling burns to heal without leaving scars. PRO SCIENCE TIP: THINK OUTSIDE THE SEARCH ENGINE Have you ever fired up Google during a brainstorming session to help your teammates generate ideas? You might think twice about doing so again. A recent study explored how creativity varies between groups when one has access to the internet and one doesn't. 244 people were divided into small groups with half of them given access to a search engine. The groups were tasked with coming up with as many ideas as possible for using a particular object. One object didn't have many results on Google when searching; the other had many. The researchers found that those who didn't use Google tended to come up with more creative and effective ideas than those who did. What's more, when there were a lot of Google search results, the groups tended to converge on the top answers given rather than coming up with their own creative responses. WHAT'S ENTERTAINING ME THIS WEEK I'm a few episodes into the new season of King of the Hill , the first since it was cancelled in 2010. The show's creators chose to advance the series in time a little bit, meaning that we get to see Hank and Peggy Hill struggling to navigate retirement while their son navigates early adulthood. If you're a fan of the original iteration, you won't be disappointed by the new episodes. And my favorite touch? In the year 2025, resident conspiracy theorist character Dale Gribble doesn't have his craziest ideas ignored anymore. Instead, he's got a Substack and a bunch of willing subscribers. MORE FROM FORBES Forbes Meet The Mastermind Behind The $1.9 Billion Poppi Deal By Chloe Sorvino Forbes As Trump Rolls Back Federal Financial Regulation, Blue State Regulators Step Up By Jeff Kauflin Forbes Why Paramount's $7.7 Billion UFC Gamble Will Pay Off By Matt Craig
